---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-055725"
form_type: "8-K"
ticker: "FLGT"
cik: "0001674930"
company_name: "Fulgent Genetics, Inc."
filed_at: "2021-11-09T23:59:59+00:00"
generated_at: "2026-06-28T10:47:51.191762+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Fulgent Genetics Q3 revenue $227.9M (+124% YoY); raises FY revenue guidance to $930M

## Summary
- Revenue $227.9M (+124% YoY); core revenue $40.1M (+292% YoY).
- GAAP net income $122.5M ($3.93 diluted EPS); non-GAAP net income $126.3M ($4.05 per share).
- Adjusted EBITDA $167.3M; cash & investments $877.3M as of Sep 30, 2021.
- Full-year 2021 revenue guidance raised to $930M from $800M.
- Billable tests ~2.2M in Q3, more than double Q3 2020.

## SEC filing metadata
- accession: 0001564590-21-055725
- form_type: 8-K
- ticker: FLGT
- cik: 0001674930
- company_name: Fulgent Genetics, Inc.
- filed_at: 2021-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674930/000156459021055725/0001564590-21-055725-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674930/000156459021055725/flgt-8k_20211109.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-055725
- JSON: https://secwatch.observer/filing/0001564590-21-055725.json
- Plain text: https://secwatch.observer/filing/0001564590-21-055725.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.